Tonix Pharmaceuticals stock rose in premarket trading as investors welcomed early adoption of its fibromyalgia drug Tonmya, with over 1,500 healthcare providers prescribing it since launch. The update comes despite a wider Q4 loss, while investors also track progress of the company Lyme disease vaccine candidate TNX-4800.